Maus Marcela V, Fraietta Joseph A, Levine Bruce L, Kalos Michael, Zhao Yangbing, June Carl H
Translational Research Program, Abramson Cancer Center and.
Annu Rev Immunol. 2014;32:189-225. doi: 10.1146/annurev-immunol-032713-120136. Epub 2014 Jan 9.
Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the treatment of cancer and certain chronic viral infections. The application of the principles of synthetic biology to enhance T cell function has resulted in substantial increases in clinical efficacy. The primary challenge to the field is to identify tumor-specific targets to avoid off-tumor, on-target toxicity. Given recent advances in efficacy in numerous pilot trials, the next steps in clinical development will require multicenter trials to establish adoptive immunotherapy as a mainstream technology.
过继性免疫疗法，即淋巴细胞输注，是一种治疗癌症和某些慢性病毒感染的有前景的方法。应用合成生物学原理增强T细胞功能已使临床疗效大幅提高。该领域的主要挑战是确定肿瘤特异性靶点，以避免肿瘤外的靶向毒性。鉴于众多试点试验在疗效方面取得的最新进展，临床开发的下一步将需要进行多中心试验，以使过继性免疫疗法成为一项主流技术。
